Sister Said ‘Skip My Baby Shower – The Guests Are All Executives’ – Until Fortune Magazine Arrived
The text came while I was calibrating a protein synthesis array in my lab. My phone buzzed on the counter and I glanced at it between readings. “Sophia’s baby shower — executive edition,” read the subject line of my sister’s message.
Below, in typical Sophia fashion, was a detailed explanation of why I shouldn’t attend. “Mirror, I need to be honest with you. This baby shower is important for my career.
My boss is coming. Her boss is coming. Half the C‑suite from Nexus Financial will be there.
These are serious people—VPs, directors, managing partners. I can’t have you there talking about working retail at the mall. It would reflect poorly on me.”
“Please understand, this isn’t personal.
It’s professional. Maybe we can do lunch after the baby comes.”
I stared at the message for a long moment, then returned to my calibration. The array’s readings were off by 0.003%.
Insignificant to most. Potentially catastrophic in my work. My phone buzzed again.
Another text from Sophia. “I know you’re hurt, but think about it from my perspective. I’ve worked so hard to get where I am.
Having my sister there in her mall uniform or whatever would undermine everything I’ve built. You get that, right?”
I replied simply. “Understood.
Congratulations on the baby.”
Her response was immediate. “Thanks for being mature about this. Love you.”
I set the phone down and looked around my laboratory.
Twenty thousand square feet of cutting‑edge biotech equipment, fourteen researchers currently working on projects that would revolutionize drug development, $127 million in venture capital funding. And my sister thought I worked retail at the mall. My name is Mirror Chin.
I’m 31 years old, and for the past seven years, my family has believed I work at a cosmetics store in the King of Prussia Mall. The truth is considerably different. I have a PhD in biochemical engineering from MIT.
I founded Biosynth Solutions when I was 24, a biotech startup focused on synthetic protein design for targeted drug delivery. We just closed our Series C funding round at an $890 million valuation. Last month, the FDA fast‑tracked two of our drug candidates.
The story doesn’t end here — it continues on the next page.
Tap READ MORE to discover the rest 🔎👇
